A Phase 1, Open-label Study In Healthy Subjects To Investigate the Pharmacokinetics Of Pf-06412562 Following Single Oral Administration Of Modified Release Formulation In Fasted And Fed States
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2015
At a glance
- Drugs PF 6412562 (Primary)
- Indications Cognition disorders
- Focus Pharmacokinetics
- Sponsors Pfizer
- 24 Nov 2014 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
- 06 Oct 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 08 Sep 2014 Protocol has been amended to change in primary outcomes that resulted in change in the trial focus from pharmacokinetics and adverse reaction to only pharmacokinetics.